Jenny Harrington, CEO Gilman Hill Asset Management, and Karen Firestone, Executive Chairman Aureus Asset Management, join ...

March 3 (Reuters) - The U.S. Food and Drug Administration has warned Novo Nordisk over a consumer ad for its blockbuster ...

The $166 ​bln Wegovy maker has ⁠effectively shed all ​its share-price gains ​from a pioneering obesity drug. The key problem: ...

​Novo Nordisk A/S (NYSE:NVO) is one of the Best Value Stocks to Buy for the Long Term. On March 2, Novo Nordisk A/S (NYSE:NVO ...

Now, it’s worth noting Stock Advisor’s total average return is 959 % — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Novo Nordisk (NVO) stock is in focus as the firm gets FDA scrutiny over an Ozempic TV ad, the second warning it received for ...

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has ...

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...

Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, ...

Less than a month after the US Food and Drug Administration said a TV advertisement for Novo Nordisk A/S’ Wegovy weight-loss ...

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a year-long campaign to ...

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50 ...